Ovulation Induction

Ovulation induction (OI) is the pharmacological stimulation of follicular development to produce ovulation in women with anovulatory or oligo-ovulatory infertility. It is distinct from controlled ovarian hyperstimulation (COH/superovulation), where the aim is to recruit multiple follicles for ART. The core NEET PG yield lies in clomiphene citrate pharmacology, letrozole, gonadotrophins, and ovarian hyperstimulation syndrome (OHSS).

Indications & selecting candidates

The single most common indication is PCOS (WHO Group II anovulation — normogonadotrophic, normo-oestrogenic). OI is the front-line fertility treatment here.

The WHO anovulation classification is a high-yield framework because it dictates the drug:

WHO Group	Hormonal profile	Prototype cause	First-line treatment
Group I	Low FSH, low LH, low oestrogen (hypogonadotrophic hypogonadism)	Hypothalamic amenorrhoea, Kallmann, weight loss/exercise	Pulsatile GnRH or gonadotrophins (FSH + LH)
Group II	Normal FSH, normal/high LH, normal oestrogen	PCOS	Letrozole / clomiphene
Group III	High FSH, low oestrogen (hypergonadotrophic hypogonadism)	Premature ovarian insufficiency	Oocyte donation (OI futile)
Hyperprolactinaemic	High prolactin	Prolactinoma	Cabergoline/bromocriptine

High-yield: OI agents work only when the hypothalamic–pituitary–ovarian (HPO) axis is intact. Clomiphene/letrozole act via the pituitary, so they fail in WHO Group I (no FSH reserve) and Group III (no follicles). Group I needs gonadotrophins; Group III needs donor eggs.

Prerequisites before starting OI — confirm: (1) ovulatory defect is the problem, (2) tubal patency (HSG) and (3) a normal semen analysis. Inducing ovulation in a woman whose partner is azoospermic or whose tubes are blocked is a classic exam "wrong step."

Clomiphene citrate — the prototype SERM

Clomiphene citrate (CC) is a selective oestrogen receptor modulator (SERM), a racemic mixture of zuclomiphene (potent, long-acting) and enclomiphene (the active, antioestrogenic isomer). It is structurally related to tamoxifen.

Mechanism (key MCQ): CC binds and blocks hypothalamic oestrogen receptors → the hypothalamus is "fooled" into perceiving low oestrogen → loss of negative feedback → increased pulsatile GnRH → increased FSH and LH → follicular recruitment. Ovulation follows the resulting endogenous gonadotrophin surge.

Dosing flow:

Day 2–5 start (commonly Day 3 or 5) → 50 mg/day × 5 days → look for ovulation (mid-luteal progesterone, follicular tracking) → if anovulatory, step up to 100 mg, then 150 mg → maximum 150 mg/day (some protocols allow short courses to higher doses, but 150 mg is the standard ceiling).

• Ovulation occurs typically 5–10 days after the last tablet.
• ~75–80% of women ovulate; only ~35–40% conceive (the "ovulation–conception gap").
• Limit to ≤6 ovulatory cycles — no added benefit beyond this and historic (now largely refuted) ovarian-cancer concerns.

High-yield: The hallmark paradox of clomiphene is a discrepancy between ovulation rate (~80%) and pregnancy rate (~40%). This is explained by its peripheral antioestrogenic effects on the cervical mucus and endometrium.

Antioestrogenic side effects — the most tested concept

Because CC blocks oestrogen receptors everywhere, not just the hypothalamus, it has peripheral antioestrogenic actions that hurt fertility even when ovulation succeeds:

Site	Antioestrogenic effect	Consequence
Cervix	Thick, scanty, hostile cervical mucus	Impaired sperm penetration/transport
Endometrium	Thin endometrium (<7 mm), poor receptivity	Reduced implantation despite ovulation
CNS/visual	Visual disturbances (scotomata, blurring)	Absolute indication to STOP the drug
Vasomotor	Hot flushes	Common, dose-related
Ovary	Multifollicular recruitment	Multiple pregnancy (~8%, mostly twins); OHSS (rare)

High-yield: Visual symptoms (scintillating scotomata) with clomiphene mandate immediate, permanent discontinuation — they may be irreversible.

High-yield: A persistently thin endometrium (<6–7 mm) on clomiphene is a recognised reason to switch to letrozole, which does not have this antioestrogenic endometrial effect.

Other adverse effects: ovarian enlargement/cysts (avoid if pre-existing cyst), abdominal distension, breast tenderness, mood changes. Multiple gestation risk is higher than letrozole.

Letrozole — aromatase inhibitor & current first-line for PCOS

Letrozole is a third-generation non-steroidal aromatase inhibitor. It blocks the conversion of androgens → oestrogens (aromatase) → lowers circulating oestrogen → reduced central negative feedback → increased FSH and follicular growth. Intra-ovarian androgen accumulation also increases follicular FSH sensitivity.

Dosing: 2.5 mg/day × 5 days from Day 3 (range 2.5–7.5 mg). Short half-life (~45 h) means it clears the system before implantation, sparing the endometrium.

High-yield: The landmark PPCOS II trial (Legro et al., NEJM 2014) showed letrozole gives higher live-birth and ovulation rates than clomiphene in PCOS. Letrozole is now the preferred first-line agent for ovulation induction in PCOS (endorsed by the international PCOS guideline and ASRM).

Clomiphene vs letrozole — must-know comparison

Feature	Clomiphene citrate	Letrozole
Class	SERM (ER antagonist)	Aromatase inhibitor
Mechanism	Blocks hypothalamic ER → ↑FSH	↓oestrogen synthesis → ↑FSH
Half-life	Long (zuclomiphene ~weeks)	Short (~45 h)
Effect on endometrium	Thins it (antioestrogenic)	Spares it
Effect on cervical mucus	Hostile/thick	Favourable
Live-birth rate in PCOS	Lower	Higher (PPCOS II)
Multiple pregnancy	Higher (~8%)	Lower (mostly monofollicular)
Teratogenicity	None proven; long half-life a theoretical concern	Initial cardiac-anomaly signal not confirmed; given pre-conception, cleared early
First-line for PCOS	Older standard	Current preferred

High-yield: Letrozole produces a more physiological, often mono-follicular response → lower multiple-pregnancy and lower OHSS risk than clomiphene/gonadotrophins.

Gonadotrophins

Used when oral agents fail (clomiphene/letrozole resistance), in WHO Group I anovulation, and in IVF/IUI superovulation. Preparations: hMG (FSH + LH activity, urinary), purified urinary FSH, and recombinant FSH (r-FSH).

• Require intensive monitoring — serial transvaginal ultrasound (follicle size) plus serum oestradiol — because of the high risk of multifollicular development.
• Ovulation triggered by hCG (mimics the LH surge) when a lead follicle reaches ≥18 mm.
• Low-dose step-up protocols reduce multiple pregnancy and OHSS in PCOS.
• Highest multiple-pregnancy and OHSS risk of all OI agents.

Adjuncts & special situations

• Metformin: insulin sensitiser; used in PCOS especially with insulin resistance/obesity. Adjunct rather than sole OI agent; may be added to clomiphene in clomiphene-resistant PCOS. Reduces OHSS risk in IVF.
• Pulsatile GnRH: physiological choice for hypothalamic amenorrhoea (WHO Group I) — delivered via a pump every ~90 minutes; low multiple-pregnancy and OHSS rates because feedback remains intact.
• Dopamine agonists (cabergoline > bromocriptine): restore ovulation in hyperprolactinaemic anovulation; cabergoline also used in OHSS prophylaxis.
• Laparoscopic ovarian drilling (LOD): second-line surgical option in clomiphene-resistant PCOS; mono-ovulatory (no multiple-pregnancy/OHSS risk) but carries risk of adhesions and diminished ovarian reserve.

High-yield: In clomiphene-resistant PCOS, options are: add metformin → switch to letrozole → gonadotrophins → laparoscopic ovarian drilling → IVF.

Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is the most dangerous iatrogenic complication of OI/COH — an exaggerated response to ovulation triggering, mediated by VEGF-driven increased vascular permeability after hCG exposure.

Pathophysiology: hCG (trigger or endogenous pregnancy hCG) → ovarian release of VEGF → increased capillary permeability → fluid shifts from intravascular to third space → ascites, pleural effusion, haemoconcentration, hypovolaemia, oliguria, and hypercoagulability.

Risk factors: young age, low BMI, PCOS, high antral follicle count, high AMH, high oestradiol, large number of follicles/oocytes, use of hCG (trigger and luteal support), and pregnancy (the worst, causing late/prolonged OHSS).

High-yield: OHSS is driven by hCG and VEGF. Clomiphene/letrozole rarely cause it; gonadotrophins are the usual culprit. Pregnancy worsens and prolongs it.

Onset patterns

• Early OHSS: within ~9 days of hCG trigger → reflects ovarian response to the trigger.
• Late OHSS: >10 days → reflects endogenous hCG from an implanting pregnancy → tends to be more severe and prolonged.

Grading (Golan classification — high-yield)

Grade	Severity	Features
Grade 1	Mild	Abdominal distension/discomfort
Grade 2	Mild	+ Nausea, vomiting, ovaries enlarged 5–12 cm
Grade 3	Moderate	+ Ultrasound evidence of ascites
Grade 4	Severe	+ Clinical ascites/hydrothorax, dyspnoea
Grade 5	Severe	+ Haemoconcentration, hypovolaemia, oliguria, coagulation/electrolyte abnormalities

Severe-OHSS red flags: haematocrit >45%, WBC >15,000, hyponatraemia, hyperkalaemia, raised creatinine, tense ascites, pleural effusion, thromboembolism. Critical OHSS = HCT >55%, WBC >25,000, renal failure, ARDS, thrombosis.

Prevention (more tested than treatment)

Identify high responder → choose mild stimulation → use GnRH-antagonist protocol → trigger with GnRH agonist instead of hCG → "freeze-all" embryos → cabergoline → coasting.

1. GnRH-agonist trigger (instead of hCG) in antagonist cycles — induces an endogenous LH surge with a short half-life → most effective single preventive measure.
2. Freeze-all / elective frozen embryo transfer — avoids pregnancy-related endogenous hCG (prevents late OHSS).
3. Cabergoline — VEGF-receptor antagonism reduces capillary leak.
4. Coasting — withholding gonadotrophins while continuing GnRH analogue.
5. Metformin in PCOS undergoing IVF; lowest-effective gonadotrophin dose; cancelling the cycle if oestradiol is dangerously high.

High-yield: The single most effective way to prevent OHSS in a high responder is to replace the hCG trigger with a GnRH-agonist trigger (and/or adopt a freeze-all strategy).

Management

Mostly supportive and self-limiting (resolves as hCG falls, unless pregnancy supervenes):

• Outpatient (mild–moderate): oral fluids, analgesia (paracetamol; avoid NSAIDs if renal compromise), monitor weight/girth/urine output, daily review.
• Inpatient (severe): IV crystalloids, human albumin for volume expansion, strict input/output, correct electrolytes, thromboprophylaxis (LMWH) — VTE risk is high and can be life-threatening.
• Tense ascites/respiratory compromise: ultrasound-guided paracentesis (relieves symptoms, improves renal perfusion); thoracocentesis for large effusions.
• Avoid: diuretics in the hypovolaemic phase (worsen haemoconcentration) and aggressive ovarian manipulation (risk of rupture/torsion).

High-yield: In severe OHSS, never give diuretics while haemoconcentrated; expand volume first with crystalloid/albumin. Always give thromboprophylaxis — death in OHSS is usually from thromboembolism (including arterial/cerebral) or ARDS.

Complications of ovulation induction (overview)

• Multiple pregnancy — highest with gonadotrophins, then clomiphene; lowest with letrozole/pulsatile GnRH.
• OHSS — as above.
• Ovarian torsion / cyst rupture in enlarged ovaries.
• Ectopic and heterotopic pregnancy — risk rises with multifollicular cycles/ART.
• Theoretical historical concern re: ovarian tumours with prolonged clomiphene — not substantiated, but the ≤6-cycle limit persists.

Key differentials / decision points

• Anovulation vs other infertility factors: always exclude tubal and male factors before OI.
• PCOS vs hypothalamic amenorrhoea vs POI: distinguished by gonadotrophin/oestrogen profile (the WHO groups) — this determines whether OI will even work.
• OHSS vs ovarian torsion vs ectopic vs intra-abdominal bleeding in a stimulated patient presenting with pain — ultrasound and HCT guide differentiation.

Recently asked / exam angle

• Mechanism of clomiphene — antioestrogen at hypothalamus → ↑GnRH/FSH/LH. Repeatedly asked.
• Why ovulation rate > pregnancy rate with clomiphene → antioestrogenic effect on cervical mucus and endometrium.
• Clomiphene side effect requiring stoppage → visual disturbance.
• Letrozole mechanism (aromatase inhibitor) and its endometrium-sparing advantage / PPCOS-II superiority in PCOS.
• OHSS mediator → VEGF; trigger → hCG; worst risk factor → pregnancy/PCOS.
• OHSS prevention → GnRH-agonist trigger, freeze-all, cabergoline, coasting.
• Golan grading — matching ascites/haemoconcentration to grade.
• WHO Group I treatment → pulsatile GnRH/gonadotrophins (clomiphene fails).
• Contraindicated step in severe OHSS → diuretics during haemoconcentration.
• First-line OI agent in PCOS (current) → letrozole.

Rapid revision

1. Letrozole is the current first-line OI agent in PCOS (PPCOS-II: higher live births than clomiphene).
2. Clomiphene = SERM; blocks hypothalamic ER → ↑FSH/LH; enclomiphene is the active isomer.
3. Clomiphene dose 50 → 100 → 150 mg/day × 5 days from Day 2–5; max 150 mg; limit ≤6 cycles.
4. Clomiphene: ovulation ~80%, pregnancy ~40% — gap due to hostile cervical mucus + thin endometrium.
5. Visual symptoms on clomiphene → stop permanently (may be irreversible).
6. Letrozole = aromatase inhibitor, 2.5 mg × 5 days; short half-life, spares endometrium, lower multiple-pregnancy/OHSS risk.
7. WHO Group I (hypogonadotrophic) → pulsatile GnRH / gonadotrophins; oral agents don't work.
8. WHO Group III (POI) → ovulation induction futile → donor oocytes.
9. OHSS is mediated by VEGF, triggered by hCG; PCOS and pregnancy are key risk factors.
10. Severe OHSS = haemoconcentration (HCT >45%), ascites, oliguria, hypercoagulability; classified by Golan grading.
11. Best OHSS prevention = GnRH-agonist trigger + freeze-all; adjunct cabergoline/coasting.
12. Severe OHSS management = fluids/albumin + thromboprophylaxis (LMWH) + paracentesis; never diuretics while haemoconcentrated. Death is usually from thromboembolism.